Evidence map›Paper›PMID 36979179›Full record

ArticleBiology2023

Dynamic Regulation Genes at Microtubule Plus Ends: A Novel Class of Glioma Biomarkers.

Wenwen Wang, Weilong Li, Lifang Pan, Lingjie Li, Yasi Xu, Yuqing Wang, Xiaochen Zhang, Shirong Zhang

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Wenwen WangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Affiliated Hangzhou First People's Hospital, Hangzhou 310053, China.ORCID 0000-0003-3375-4899
Weilong LiSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Affiliated Hangzhou First People's Hospital, Hangzhou 310053, China.
Lifang PanTranslational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Lingjie LiTranslational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Yasi XuSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Affiliated Hangzhou First People's Hospital, Hangzhou 310053, China.
Yuqing WangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Affiliated Hangzhou First People's Hospital, Hangzhou 310053, China.
Xiaochen ZhangDepartment of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310006, China.
Shirong ZhangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Affiliated Hangzhou First People's Hospital, Hangzhou 310053, China.
Zhejiang Chinese Medical University · CNZhejiang University · CN

Funding

Hangzhou Medical and Health Science and Technology Project A20200827Zhejiang Provincial Medical and Health Science and Technology Project WKJ-ZJ-2331Zhejiang Provincial Natural Science Foundation LY23C070002
6 · The paper itself

Abstract

Glioma is the most prevalent and aggressive primary nervous system tumor with an unfavorable prognosis. Microtubule plus-end-related genes (MPERGs) play critical biological roles in the cell cycle, cell movement, ciliogenesis, and neuronal development by coordinating microtubule assembly and dynamics. This research seeks to systematically explore the oncological characteristics of these genes in microtubule-enriched glioma, focusing on developing a novel MPERG-based prognostic signature to improve the prognosis and provide more treatment options for glioma patients. First, we thoroughly analyzed and identified 45 differentially expressed MPERGs in glioma. Based on these genes, glioma patients were well distinguished into two subgroups with survival and tumor microenvironment infiltration differences. Next, we further screened the independent prognostic genes (

Indexed as

biomarkerdrug responsegliomaimmunotherapymicrotubule plus-end-related genetumor microenvironment

Identifiers

PMID36979179
PMCPMC10045452
OpenAlexW4360613971

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read26
table measurements read4
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.